- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06002763
Évaluation du système d'information sur la mesure des résultats rapportés par les patients (PROMIS)-29 v2.1 pour les femmes en post-partum
There is no widely used, statistically validated assessment for physical and mental health for the short- to medium-term in a postpartum population. PROMIS-29 has been validated for the assessment of these factors in a generic population, but has not been specifically evaluated for use with postpartum women.
This study is a longitudinal, single center observational cohort study designed to evaluate the reliability of the Patient-Reported Outcomes Measurement Information System (PROMIS)-29 v2.1 survey in a postpartum population. PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living. While this survey has shown utility in other populations, it has yet to be assessed in an obstetric population. The investigators plan to recruit patients who are recently postpartum from vaginal or cesarean delivery to complete virtual surveys at defined time points (0, 2, 6, and 12 weeks after delivery). The investigators will subject survey data to statistical measures of validity and reliability comparing with contemporaneously collected surveys of established metrics for quality of life (WHOQoLBREF) and general (global) state of health (numerical rating score 1-100).
The hypothesis is that the PROMIS-29 v2.1 questionnaire is a statistically valid and reliable means of assessing physical and mental health in a postpartum population.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Ontario
-
Toronto, Ontario, Canada, M5G1X5
- Mount Sinai Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients who deliver vaginally or by scheduled cesarean section at Mount Sinai Hospital.
La description
Inclusion Criteria:
- 18 years old and over
- singleton births
- 37 or more weeks gestational age
- multiparous or nulliparous patients
- spontaneous vaginal delivery or scheduled cesarean delivery with labor analgesia or neuraxial anesthesia
- give informed written consent
Exclusion Criteria:
- refusal to take part
- are unable to give or have withdrawn consent
- patients unable to communicate fluently in English
- patients who are less than 18 years old
- patients who had fetal demise or severely morbid fetal conditions such as intubation, cooling, expected surgical correction of congenital anomaly during hospitalization (although NICU admissions will be included)
- patients who were admitted in ICU
- patients who had failed neuraxial analgesia such as replaced epidurals or failed spinal requiring conversion to general anesthesia
- patients who had general anesthesia for cesarean delivery as defined by "GETA", including sedatives and deep sedation if not intubated
- patients who had intrapartum cesarean or had assisted/operative (i.e. vacuum, forceps) vaginal delivery.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Vaginal delivery
Patients who have vaginal deliveries with neuraxial labour analgesia. |
PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living.
Autres noms:
The WHOQOL-BREF is a 26-item version of the 100-item WHOQOL-100 quality of life measure that addresses four quality of life domains: physical health, psychological health, social relationships and environment.
Autres noms:
The EQ-5D-3L1 is a generic measure of health status consisting of two parts. The first part assesses health in five dimensions: MOBILITY, SELFCARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY/DEPRESSION. The second part of the questionnaire consists of a VAS on which the patient rates their perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).
Autres noms:
|
|
Cesarean delivery
Patients who have a scheduled cesarean delivery with neuraxial anesthesia. |
PROMIS-29 is a survey designed to screen for pain, impairments in mood, physical function, and activities of daily living.
Autres noms:
The WHOQOL-BREF is a 26-item version of the 100-item WHOQOL-100 quality of life measure that addresses four quality of life domains: physical health, psychological health, social relationships and environment.
Autres noms:
The EQ-5D-3L1 is a generic measure of health status consisting of two parts. The first part assesses health in five dimensions: MOBILITY, SELFCARE, USUAL ACTIVITIES, PAIN / DISCOMFORT, ANXIETY/DEPRESSION. The second part of the questionnaire consists of a VAS on which the patient rates their perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System) survey score
Délai: 24 hours
|
The PROMIS survey score at 24 hours postpartum |
24 hours
|
|
WHOQoLBREF (World Health Organization Quality of Life Brief Version) survey score
Délai: 24 hours
|
The WHOQoLBREF survey score at 24 hours postpartum |
24 hours
|
|
EQ-5D-3L1 (not an acronym) survey score
Délai: 24 hours
|
The EQ-5D-3L1 survey score at 24 hours postpartum |
24 hours
|
|
PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System) survey score
Délai: 2 weeks
|
The PROMIS survey score at 2 weeks postpartum |
2 weeks
|
|
WHOQoLBREF (World Health Organization Quality of Life Brief Version) survey score
Délai: 2 weeks
|
The WHOQoLBREF survey score at 2 weeks postpartum |
2 weeks
|
|
EQ-5D-3L1 (not an acronym) survey score
Délai: 2 weeks
|
The EQ-5D-3L1 survey score at 2 weeks postpartum |
2 weeks
|
|
PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System) survey score
Délai: 6 weeks
|
The PROMIS survey scores at 6 weeks postpartum |
6 weeks
|
|
WHOQoLBREF (World Health Organization Quality of Life Brief Version) survey score
Délai: 6 weeks
|
The WHOQoLBREF survey score at 6 weeks postpartum |
6 weeks
|
|
EQ-5D-3L1 (not an acronym) survey score
Délai: 6 weeks
|
The EQ-5D-3L1 survey score at 6 weeks postpartum |
6 weeks
|
|
PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System) survey score
Délai: 12 weeks
|
The PROMIS survey score at 12 weeks postpartum |
12 weeks
|
|
WHOQoLBREF (World Health Organization Quality of Life Brief Version) survey score
Délai: 12 weeks
|
The WHOQoLBREF survey score at 12 weeks postpartum |
12 weeks
|
|
EQ-5D-3L1 (not an acronym) survey score
Délai: 12 weeks
|
The EQ-5D-3L1 survey score at 12 weeks postpartum |
12 weeks
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Ronald George, MD, MOUNT SINAI HOSPITAL
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 23-03
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .